EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parkinson's‐Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa

Julian R Mark, Hannah A Staley, Ann M Titus, Julian Agin-Liebes, Alicia Garrido, Laura Hughes, Nicolas Dzamko iD, Rebecca L Wallings, Malú Gámez Tansey iD

Movement Disorders · 2026

DOI: 10.1002/mds.70123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Julian R Mark und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, University of Florida, College of Medicine, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Pseudomonas aeruginosa, Glucosylceramidase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shake It Up Australia Foundation, Michael J. Fox Foundation for Parkinson's Research, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peripheral disease mechanisms such as immune dysregulation may contribute to Parkinson's disease ( PD ). To investigate interactions between common PD mutations and immune responses to environmental pathogens, we studied responses to Pseudomonas aeruginosa ( P. aeruginosa ) in peripheral blood mononuclear cells ( PBMCs ) from PD patients with leucine‐rich repeat kinase 2 ( LRRK2 ) mutations, GBA1 mutations, and idiopathic disease ( iPD ) relative to neurologically healthy controls ( NHC ).

Objectives

The goal was to test the hypothesis that LRRK2 and GBA modify the human peripheral immune response to bacteria, specifically P. aeruginosa , based on prior animal studies involving Lrrk2 mutations and microbial pathogens.

Methods

PBMCs from LRRK2 ‐ PD , GBA ‐ PD , and iPD patients plus age‐ and sex‐matched controls were treated ex vivo with live P. aeruginosa and pharmacological agents that block LRRK2 kinase activity ( MLi ‐2) or enhance glucocerebrosidase ( GCase ) activation ( NCGC00188758 ) to measure enzymatic activities and cytokine release.

Results

GBA ‐ PD PBMCs exhibited increased P. aeruginosa ‐dependent secretion of specific inflammatory cytokines including interleukin ‐1β. Antigen presentation was increased in LRRK2 ‐ PD nonclassical monocytes treated with the GCase activator. Levels of pRab10 , a proxy for LRRK2 kinase activity, were increased in GBA ‐ PD classical monocytes relative to NHC and iPD . GCase activator treatment increased pRab10 expression in LRRK2 ‐ PD intermediate monocytes. GBA ‐ PD and individual treatments with MLi ‐2 or GCase activator were associated with reduced P. aeruginosa ‐dependent LRRK2 protein levels in PBMC subsets.

Conclusions

This work demonstrates that PD ‐linked mutations in LRRK2 and GBA1 converge on peripheral blood immune cell dysregulation, as evinced by the ability of LRRK2 inhibitors and GCase activators to modulate the ex vivo immune response to bacterial exposure. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseasePseudomonas aeruginosaGlucosylceramidaseLeukocytes, MononuclearHumansMaleFemaleMiddle AgedMutationAged

Stichwörter der Autor:innen

GBA1LRRK2Parkinson's Diseaseglucocerebrosidaseinflammation

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2GlucosylceramidaseLRRK2 protein, humanGBA protein, human

Autor:innen und Institutionen

  • Department of Neuroscience, University of Florida, College of Medicine, Gainesville, FL, USA.
  • Center for Translational Research in Neurodegenerative Disease, University of Florida, College of Medicine, Gainesville, FL, USA.
  • Trinity College of Arts and Sciences, Duke University, Durham, NC, USA.
  • Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
  • Parkinson's Disease and Movement Disorders Unit Institut Clínic de Neurociències Hospital Clinic de Barcelona, Barcelona, Spain.
  • Medicine and Health, University of Sydney, Sydney, NSW, Australia.

ORCID-Profile: Nicolas Dzamko, Malú Gámez Tansey

Förderung

  • Shake It Up Australia Foundation
  • Michael J. Fox Foundation for Parkinson's Research
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mark, J. R., Staley, H. A., Titus, A. M., Agin-Liebes, J., Garrido, A., Hughes, L., Dzamko, N., Wallings, R. L., & Tansey, M. G. (2026). Parkinson's‐Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa. Movement Disorders. https://doi.org/10.1002/mds.70123

Vancouver

Mark JR, Staley HA, Titus AM, Agin-Liebes J, Garrido A, Hughes L, et al. Parkinson's‐Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa. Movement Disorders. 2026. doi:10.1002/mds.70123

BibTeX
@article{Mark2026,
  author = {Mark, Julian R and Staley, Hannah A and Titus, Ann M and Agin-Liebes, Julian and Garrido, Alicia and Hughes, Laura and Dzamko, Nicolas and Wallings, Rebecca L and Tansey, Malú Gámez},
  title = {Parkinson's‐Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70123}
}
Kostenlos starten →